Answers are grounded in this paper and cite their sources.
Background/Objectives: Neurofibromatosis type 1 (NF1) has variable clinical expression and marked allelic heterogeneity. This study assessed the diagnostic yield of molecular testing in a regional Romanian cohort with an initial clinical diagnosis of NF1 and described the clinical features of patients with NF1 molecular findings. Methods: This retrospective study included 77 patients evaluated between 1990 and 2025. We reviewed the use and results of next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA), and fluorescence in situ hybridization (FISH). Results: Of the 77 patients, 42 (54.5%) underwent molecular testing. NGS was performed in 36 patients, MLPA in 15, and FISH in 7. NGS identified pathogenic or likely pathogenic NF1 sequence variants in 30 of 36 sequenced patients (83.3%), representing 30 of 42 tested patients (71.4%). In one additional patient with a negative NGS result, MLPA detected a suspected intragenic NF1 deletion that was not independently confirmed. Including this finding, the observed yield was 31/36 (86.1%) among sequenced patients and 31/42 (73.8%) among all tested patients. FISH detected no 17q11.2 microdeletions. One patient had an NF1 variant of uncertain significance. Each of the three recurrent NF1 variants was observed within a single family. A homozygous pathogenic MSH6 variant led to the reclassification of one patient as having constitutional mismatch repair deficiency (CMMRD). Conclusions: NGS identified a pathogenic or likely pathogenic NF1 variant in 30 of the 36 sequenced patients. Because access to testing and the methods used varied across the cohort, this proportion applies to the sequenced subgroup. In one child initially diagnosed with NF1, molecular testing established a diagnosis of CMMRD.
No takes yet. Share an insight, caveat, or question.
Jurca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: